Call for Proposals

Learn more about our Call for Proposals

The conference will provide a leading interdisciplinary platform for all stakeholders of the pharmaceutical chain. These sessions and workshops will showcase recent innovations and trends, and directly discuss practical challenges and solutions, from a technical, logistical, and regulatory perspective. The impact of Quality Risk Management (QRM) and Contamination Control Strategy (CCS) regulations, in particular for Annex 1, will be integrated throughout the conference programme and discussions. Participants will have the opportunity to engage with industry leaders, regulators, and peers through networking events and the conference programme.

The submission period has ended.

Call for Proposals Timeline

DateAction
25 Mar 2024Opens
20 May 2024Submission Deadline
28 Jun 2024Notifications

Presentation Type

Abstract submissions may be proposed for the following:

Individual Oral Presentation 

20-minute presentation, to be made part of a track by the Planning Committee. The presentation should focus on new and innovative trends, a specific real-world strategy or campaign, a case study/use case, or a “how-to" presentation intended to help attendees gain a better understanding of the initiative and best practices that can be applied to day-to-day objectives or overall mission.

Content Areas

The 2024 ISPE Pharma 4.0™ and Annex 1 Conference International Programme Committee are requesting proposals aligning with the following content areas:

Annex 1 Implementation & Pharma 4.0 

The EU GMP Annex 1 is an enabler for the implementation of new innovations in sterile/aseptic manufacturing. Continuous Monitoring for Contamination Control Management, rapid microbial testing, automation with robots, Digitalization, validated and automated material transfers, and containment as barriers are some of the keywords for the Pharma 4.0 transformation. Regulatory agencies, industry, and solutions/innovation providers need to collaborate to enable this transformation for the highest safety of sterile pharmaceutical manufacturing. 

 

How ATMPs Manufacturing Can Be Supported by Annex 1 and Digital Transformation 

Advanced Therapies Medicinal Products are on an increasing curve in the pharmaceutical market. These products are essential for patients. As for some products, the starting material comes from the patient, failing a batch is not an option. How can the industry deliver safe products to patients improving their processes and Annex 1 implementation and using more data management to have faster product release? This track will consider autologous and allogeneic Cell Therapy and Gene Therapies products. 

If you have practices of these operations with the support of “aseptic” processes and using digital transformation with more data generated by the process control, you are welcome to share your experience related to the following topics: 

  • How to avoid cross-contamination Closed Processes Benefits of digital transformation, Pharma 4.0 in this area 
  • How to improve contamination prevention in these products with process control, process design, and facilities design 
  • How to improve process understanding by using digital methods 
  • How to support batch release for products with a short shelf life 
  • Could Artificial Intelligence and/or Machine learning be beneficial for such applications 

This list is not exhaustive; we are excited to receive your proposal to build a robust track around ATMPs with the support of Annex 1 and Pharma 4.0. 

 

Pharma 4.0 - Case Studies and Lessons Learned 

The Digital Business Transformation requires Business Process changes supported by enabling technologies. Implementing these technologies alone is not the right answer to the challenges that our industry must face, but they are a key element of a wider solution, inclusive of revised business and compliance processes, and innovative and sustainable digital solutions. 

New opportunities offered by emerging technologies are changing the game and making new scenarios possible, even the ones considered impossible a few years ago. Our goal is to deep dive into transformation by presenting Case Studies to achieve benefits from digital solutions. These case studies are based on the enabling technologies such as Smart Wearables, Collaboration Platforms, Generative AI, Machine Learning, Advanced Robotics, Augmented Reality, and Virtual Reality, as well as less mature technologies in our industry such as Blockchain, Speech and Gesture Recognition, Edge Computing, and Quantum Computing. This track will highlight practical applications of these technologies in industry case studies, including benefits, challenges, and lessons learned. 

 

Pharma 4.0 Interconnected Facility Design and Construction 

The integration of Pharma 4.0 strategies into facility design and construction requires a forward-thinking and transformative approach to pharmaceutical manufacturing. Embracing 'plug and produce' principles presents both opportunities for an integrated and interconnected facility, as well as challenges. It necessitates agile infrastructure capable of supporting modular and flexible production systems and interconnectivity. Case studies reveal that while implementation complexity is a hurdle, the benefits of enhanced efficiency, scalability, and compliance are compelling. 

 

Workshop: Aseptic Processes and Pharma 4.0 

We plan to organise a 2.5-hour workshop session around Annex 1 implementation and discussions about where Annex 1 makes sense for the manufacturing of ATMPs with the support of Pharma 4.0. If you have already implemented new technologies to improve aseptic processes, we encourage you to submit a workshop proposal to discuss these points with conference attendees. 

We will have a short presentation to set up the scene, followed by break-out sessions that will allow participants to find ideas to make proposals around the problem statement developed during the starting presentation. The programme committee is excited to read your proposal.

Proposal Guidelines

  • All presentations must be free of commercial intent. Incomplete proposals will not be considered.
  • By submitting a proposal, you acknowledge that, if your proposal is accepted, the speaker will attend/present in-person at the event and their organization will support the speaker’s attendance at the event.
  • Accepted speakers are responsible for their own travel and accommodations.
  • Speakers giving at least a 20-minute presentation (not including Q&A) receive complimentary conference registration.
  • NOTE: Exhibitors who are accepted to present are required to register as a paid conference attendee (with discounted registration rate). Complimentary booth staffing registrations cannot be utilized for the presentations as these are part of the education sessions and not the exhibition.
  • Consulting firms or vendors/suppliers are expected to include a speaker from an owner company to present.
  • Regulators interested in submitting a proposal: Please contact Brandy Berry (bberry@ispe.org) to submit your abstract.